nach oben

Journal für Endokrinologie, Diabetologie und Stoffwechsel

Erschienen in:

30.12.2022 | Originalien

Hormonpumpen

verfasst von: Birgit Reinhart-Steininger, Ingrid Schütz-Fuhrmann, Thomas M. Stulnig

Erschienen in: Journal für Endokrinologie, Diabetologie und Stoffwechsel | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Medizinische Pumpensysteme ermöglichen die akkurate Gabe eines Medikaments in Form einer kontinuierlichen Infusion und/oder rezidivierenden Bolusgabe über einen Katheter in das subkutane Fettgewebe, nach intravenös oder auch intrathekal. Sie erleichtern den Alltag der PatientInnen, da andernfalls die häufige Selbstinjektion des Medikaments notwendig wäre, was nicht nur schmerzbehaftet sein kann, sondern tagsüber sowie unter Umständen auch nachts eine aktive Handlung des Patienten erfordert. Darüber hinaus können Hormonpumpen den physiologischen Stoffwechselprozess oft besser nachahmen, was für manche endokrine Erkrankungen eine Behandlung überhaupt erst ermöglicht. In diesem Review konzentrieren wir uns auf die Hauptanwendungsgebiete subkutaner Hormonpumpensysteme, nämlich den Diabetes mellitus Typ 1 (T1DM) sowie Anwendungen in der Gynäkologie und Reproduktionsmedizin, insbesondere bei hypothalamischer Insuffizienz.

Vorheriger Artikel Tyrosinkinaseinhibitoren bei Patienten mit radiojodrefraktärem differenziertem Schilddrüsenkarzinom

Nächster Artikel 25. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel (ÖGES) gemeinsam mit der Österreichischen Schilddrüsengesellschaft (OSDG) und der Austrian Neuroendocrine Tumor Society (ANETS)

Ostrovski I et al (2020) Analysis of prevalence, magnitude and timing of the dawn phenomenon in adults and adolescents with type 1 diabetes: descriptive analysis of 2 insulin pump trials. Can J Diabetes 44:229CrossRefPubMed

Thomas A (2010) Diabetes und Technologie, Geschichte der Insulinpumpentherapie

Battelino T et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42(8):1593–1603. https://doi.org/10.2337/dci19-0028CrossRefPubMedPubMedCentral

Agarwal S, Cappola AR (2020) Continuous glucose monitoring in adolescent, young adult, and older patients with type 1 diabetes. JAMA 323(23):2384–2385. https://doi.org/10.1001/jama.2020.7058CrossRefPubMedPubMedCentral

Ly TT, Nicholas JA, Retterath A et al (2013) Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 310:1240–1247CrossRefPubMed

Thomas MG et al (2021) Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: pump or sensor first? A meta-analysis using pooled differences in outcome measures. Diabetes Obes Metab 23(11):2521–2528. https://doi.org/10.1111/dom.14498CrossRefPubMed

Bergenstal RM et al (2013) Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 369:224–232CrossRefPubMed

Forlenza GP et al (2018) Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care 41:2155–2161CrossRefPubMed

Walsh J, Roberts R, Heinemann L (2014) Confusion regarding duration of insulin action: a potential source for major insulin dose errors by bolus calculators. J Diabetes Sci Technol 8(1):170–178. https://doi.org/10.1177/1932296813514319CrossRefPubMedPubMedCentral

10.

Klupa T et al (2011) The dual-wave bolus feature in type 1 diabetes adult users of insulin pumps. Acta Diabetol 48(1):11–14. https://doi.org/10.1007/s00592-009-0173-9CrossRefPubMed

11.

Ramotowska A, Golicki D, Dżygało K, Szypowska A (2013) The effect of using the insulin pump bolus calculator compared to standard insulin dosage calculations in patients with type 1 diabetes mellitus—systematic review. Exp Clin Endocrinol Diabetes 121(5):248–254. https://doi.org/10.1055/s-0032-1331708CrossRefPubMed

12.

Bergenstal RM et al (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316:1407–1408CrossRefPubMed

13.

Brown SA et al (2019) Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 381:1707–1717CrossRefPubMedPubMedCentral

14.

Lal RA, Basina M, Maahs DM et al (2019) One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care 42:2190–2196CrossRefPubMedPubMedCentral

15.

Garg SK et al (2017) Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 19:155–163CrossRefPubMedPubMedCentral

16.

Weisman A et al (2017) Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol 5(7):501–512. https://doi.org/10.1016/S2213-8587(17)30167-5CrossRefPubMed

17.

Ekhlaspour L et al (2022) Outcomes in baseline hemoglobin A1C subgroups in the international diabetes closed-loop 18 trial. Diabetes Technol Ther 24(8):588–591CrossRefPubMed

18.

Quemerais MA et al (2014) Preliminary evaluation of a new semi-closed-loop insulin therapy system over the prandial period in adult patients with type 1 diabetes: the WP6.0 Diabeloop study. J Diabetes Sci Technol 8(6):1177–1184. https://doi.org/10.1177/1932296814545668CrossRefPubMedPubMedCentral

19.

Nimri R et al (2020) Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nat Med 26(9):1380–1384. https://doi.org/10.1038/s41591-020-1045-7CrossRefPubMed

20.

Jennings P, Hussain S (2020) Do-it-yourself artificial pancreas systems: a review of the emerging evidence and insights for healthcare professionals. J Diabetes Sci Technol 14:868–877CrossRefPubMed

21.

Braune K, OPEN International Healthcare Professional Network and OPEN Legal Advisory Group et al (2022) Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol 10(1):58–74. https://doi.org/10.1016/S2213-8587(21)00267-9 (Erratum in: Lancet Diabetes Endocrinol. 2022 Jan;10(1):e1)CrossRefPubMed

22.

Blauw H et al (2021) Fully closed loop glucose control with a bihormonal artificial pancreas in adults with type 1 diabetes: an outpatient, randomized, crossover trial. Diabetes Care 44(3):836–838. https://doi.org/10.2337/dc20-2106CrossRefPubMed

23.

Castellanos LE et al (2021) Performance of the insulin-only ilet bionic pancreas 17 and the bihormonal ilet using dasiglucagon in adults with type 1 diabetes in a home-use 18 setting. Diabetes Care 44(6):e118–e120CrossRefPubMedPubMedCentral

24.

Haidar A et al (2020) A novel dual-20 hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized 21 controlled crossover trial. Diabetes Care 43(3):597–606CrossRefPubMed

25.

Steineck I, Swedish National Diabetes Register et al (2015) Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ 350:h3234. https://doi.org/10.1136/bmj.h3234CrossRefPubMedPubMedCentral

26.

Holesh JE et al (2022) Physiology, ovulation. StatPearls, Treasure Island (FL)

27.

Crowley WF Jr et al (1981) Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 52:370–372CrossRefPubMed

28.

Topaloglu AK et al (2009) TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 41:354–358CrossRefPubMed

29.

Herbison AE (2018) The gonadotropin-releasing hormone pulse generator. Endocrinology 159(11):3723–3736. https://doi.org/10.1210/en.2018-00653CrossRefPubMed

30.

Whitlock KE (2005) Origin and development of GnRH neurons. Trends Endocrinol Metab 16:145–151CrossRefPubMed

31.

Schwanzel-Fukuda M (1989) Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Brain Res Mol Brain Res 6:311–326CrossRefPubMed

32.

Soussi-Yanicostas N et al (1998) Anosmin‑1 underlying the X chromosome-linked Kallmann syndrome is an adhesion molecule that can modulate neurite growth in a cell-type specific manner. J Cell Sci 111(19):2953–2965CrossRefPubMed

33.

Caron P et al (1999) Resistance of hypogonadic patients with mutated GnRH receptor genes to pulsatile GnRH administration. J Clin Endocrinol Metab 84:990–996CrossRefPubMed

34.

Sykiotis GP et al (2010) Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab 95:3019–3027CrossRefPubMedPubMedCentral

35.

Ankarberg-Lindgren C et al (2001) Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab 86:3039–3044PubMed

36.

Bergadá I, Bergadá C (1995) Long term treatment with low dose testosterone in constitutional delay of growth and puberty: effect on bone age maturation and pubertal progression. J Pediatr Endocrinol Metab 8:117–122CrossRefPubMed

37.

Balasubramanian R, Crowley WF Jr. (2007) Isolated gonadotropin-releasing hormone (GnRH) deficiency. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (Hrsg) GeneReviews. University of Washington, Seattle

38.

Martin KA et al (1993) Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 77:125–129PubMed

39.

Suh BY et al (1988) Hypercortisolism in patients with functional hypothalamicamenorrhea. J Clin Endocrinol Metab 66:733–739CrossRefPubMed

40.

Sophie Gibson ME et al (2020) Where have the periods gone? The evaluation and management of functional hypothalamic amenorrhea. J Clin Res Pediatr Endocrinol 12(1):18–27. https://doi.org/10.4274/jcrpe.galenos.2019.2019.S0178CrossRefPubMedPubMedCentral

41.

Couzinet B et al (1999) Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Clin Endocrinol (Oxf) 50:229–235CrossRefPubMed

42.

Bomba M et al (2007) Endocrine profiles and neuropsychologic correlates of functional hypothalamic amenorrhea in adolescents. Fertil Steril 87:876–885CrossRefPubMed

43.

Golden NH, Carlson JL (2008) The pathophysiology of amenorrhea in the adolescent. Ann N Y Acad Sci 1135:163–178CrossRefPubMed

44.

Gordon CM (2010) Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med 363:365–371CrossRefPubMed

45.

Shufelt CL et al (2017) Hypothalamic amenorrhea and the long-term health consequences. Semin Reprod Med 35(3):256–262. https://doi.org/10.1055/s-0037-1603581CrossRefPubMedPubMedCentral

46.

47.

Dumont A et al (2016) Comparison between pulsatile GnRH therapy and gonadotropins for ovulation induction in women with both functional hypothalamic amenorrhea and polycystic ovarian morphology. Gynecol Endocrinol 32:999–1004CrossRefPubMed

48.

Wildt L et al (2019) Pulsatile GnRH-Therapie. In: Diedrich K, Ludwig M, Griesinger G (Hrsg) Reproduktionsmedizin. Springer, Berlin, Heidelberg

49.

Begon S et al (1993) Pulsatile administration of gonadotrophin releasing hormone as a diagnostic tool to distinguish hypothalamic from pituitary hypogonadism following neurosurgery. Hum Reprod 8(2):200–203CrossRefPubMed

50.

Leyendecker G, Struve T, Plotz EJ (1980) Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea. Arch Gynecol 229:177–190. https://doi.org/10.1007/BF02108310CrossRefPubMed

51.

Liu Z et al (2015) Effectiveness and safety of pulsatile GnRH pump therapy on female patients with IHH. Zhonghua Yi Xue Za Zhi 95(42):3432–3435PubMed

52.

Hao M et al (2021) Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy in patients with congenital hypogonadotropic hypogonadism: a multicentre clinical study. Ann Transl Med 9(12):962. https://doi.org/10.21037/atm-21-1632CrossRefPubMedPubMedCentral

53.

Tranoulis A et al (2018) Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. Fertil Steril 109:708–719CrossRefPubMed

54.

Filicori M et al (1991) Ovulation induction with pulsatile gonadotropin-releasing hormone: technical modalities and clinical perspectives. Fertil Steril 56:1–13CrossRefPubMed

55.

Filicori M, Cognigni GE (2018) Ovulation induction with pulsatile gonadotropin releasing hormone: missing in action. Fertil Steril 109(4):621–622. https://doi.org/10.1016/j.fertnstert.2018.01.023CrossRefPubMed

56.

Filicori M et al (1994) Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 79:1215–1220PubMed

57.

Filicori M et al (1988) Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH. J Clin Endocrinol Metab 66(2):327–333. https://doi.org/10.1210/jcem-66-2-327CrossRefPubMed

58.

Homburg R et al (1989) One hundred pregnancies after treatment with pulsatile luteinising hormone releasing hormone to induce ovulation. BMJ 298(6676):809–812. https://doi.org/10.1136/bmj.298.6676.809CrossRefPubMedPubMedCentral

59.

Castillo JC et al (2020) Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention. Ups J Med Sci 125(2):138–143. https://doi.org/10.1080/03009734.2020.1737599CrossRefPubMedPubMedCentral

60.

Liu L et al (1988) Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 67(6):1140–1145. https://doi.org/10.1210/jcem-67-6-1140CrossRefPubMed

61.

Pitteloud N et al (2002) Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 87:4128–4136CrossRefPubMed

62.

Rastrelli G et al (2014) Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology 2(6):794–808CrossRefPubMed

63.

Wildt L, Böttcher B, Leyendecker G (2019) Pulsatile GnRH-Therapie. In: Diedrich K, Ludwig M, Griesinger G (Hrsg) Reproduktionsmedizin. Springer, Berlin, Heidelberg, S 1–14 https://doi.org/10.1007/978-3-662-55601-6_16-1CrossRef

Titel: Hormonpumpen
verfasst von: Birgit Reinhart-Steininger
Ingrid Schütz-Fuhrmann
Thomas M. Stulnig
Publikationsdatum: 30.12.2022
Verlag: Springer Vienna
Erschienen in: Journal für Endokrinologie, Diabetologie und Stoffwechsel / Ausgabe 1/2023
Print ISSN: 3004-8915
Elektronische ISSN: 3004-8923
DOI: https://doi.org/10.1007/s41969-022-00184-x

Warum bekommen übergewichtige Menschen häufiger Erkrankungen?

aktuell

Ernährungsanpassungen bei diabetischer Nierenerkrankung

aktuell

Neue Schutzfunktion von Antidiabetika nachgewiesen

aktuell

Editorial

Editorial

Autofluoreszenz der Nebenschilddrüsen in der Schilddrüsenchirurgie

Open Access
Originalien

25. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel (ÖGES) gemeinsam mit der Österreichischen Schilddrüsengesellschaft (OSDG) und der Austrian Neuroendocrine Tumor Society (ANETS)

Abstracts

Springer Medizin Österreich

Hormonpumpen

Zusammenfassung

Weitere Artikel der Ausgabe 1/2023

Warum bekommen übergewichtige Menschen häufiger Erkrankungen?

Ernährungsanpassungen bei diabetischer Nierenerkrankung

Neue Schutzfunktion von Antidiabetika nachgewiesen

Editorial

Autofluoreszenz der Nebenschilddrüsen in der Schilddrüsenchirurgie

25. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel (ÖGES) gemeinsam mit der Österreichischen Schilddrüsengesellschaft (OSDG) und der Austrian Neuroendocrine Tumor Society (ANETS)

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Warum bekommen übergewichtige Menschen häufiger Erkrankungen?

Ernährungsanpassungen bei diabetischer Nierenerkrankung

Neue Schutzfunktion von Antidiabetika nachgewiesen

Editorial

Autofluoreszenz der Nebenschilddrüsen in der Schilddrüsenchirurgie

25. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel (ÖGES) gemeinsam mit der Österreichischen Schilddrüsengesellschaft (OSDG) und der Austrian Neuroendocrine Tumor Society (ANETS)